drugset / Trial / NCT02201056
Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to characterize the safety and tolerability profile of TAK-935 in healthy participants when administered as a single dose of oral solution at escalating dose levels.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Soticlestat | Small molecule | 15 mg | Oral |
| Subject | Soticlestat | Small molecule | 50 mg | Oral |
| Subject | Soticlestat | Small molecule | 200 mg | Oral |
| Subject | Soticlestat | Small molecule | 600 mg | Oral |
| Subject | Soticlestat | Small molecule | 900 mg | Oral |
| Subject | Soticlestat | Small molecule | 1350 mg | Oral |
Indications
No indication recorded.